ENTERALIA BIOSCIENCE S.R.L.

What ENTERALIA BIOSCIENCE S.R.L. does

Enteralia Bioscience S.r.l. is an Italian private limited company (S.r.l.) headquartered in Monza, Italy, founded in 2020. Per firmographic self-description, the company develops therapeutic and nutritional solutions for gastrointestinal, iron deficiency, and gynecological disorders. However, the supporting product and service data describe a healthcare market-access role: in 2026, Enteralia co-founded the European Healthcare Alliance (EHA) alongside NEMYSIS Ltd. and RICERCHIMA S.r.l., a members-only digital platform (eha-network.com) designed to connect non-EU healthcare companies with European licensing partners and consultants across pharmaceuticals, medical devices, food supplements, and cosmetics. The detailed data does not substantiate the therapeutic/nutritional product line with pipeline, manufacturing, or regulatory filings, so the EHA platform is the only documented operational activity.

The business model is not explicitly disclosed. The EHA platform appears to be a marketplace/intermediation service built around licensing assets, partner search, and consulting — addressing regulatory navigation and partnership identification for non-EU entrants to European healthcare markets. No pricing model, customer-billing mechanism, or revenue stream is publicly disclosed. No management team, employee count, or ownership structure is available in the provided data.

Strategically, the company is at an early stage. No funding rounds, headcount figures, customer logos, patents, certifications, or regulatory actions are disclosed. The EHA co-founding is the most significant documented event, suggesting the company's near-term focus is on building a multi-vertical healthcare ecosystem rather than scaling a proprietary therapeutic franchise. The lack of disclosed financials, headcount, and leadership means the investment case rests almost entirely on the still-unproven EHA platform and the unresolved question of whether Enteralia's self-described therapeutic/nutritional business is operational.

Name

ENTERALIA BIOSCIENCE S.R.L.

Legal name

ENTERALIA BIOSCIENCE S.R.L.

Website

https://enteralia.it

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Enteralia Bioscience S.r.l. is an Italian private healthcare company that co-founded the European Healthcare Alliance (EHA) in 2026, a digital platform connecting non-EU healthcare companies with European licensing partners and consultants across pharmaceuticals, medical devices, food supplements, and cosmetics.

Ownership category

akta.pro rank

Headquarters

HQ city

Monza

HQ country

Italy

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

ENTERALIA BIOSCIENCE S.R.L. develops therapeutic and nutritional solutions targeting gastrointestinal, iron deficiency, and gynecological disorders. The company is also a co-founder of the European Healthcare Alliance (EHA), a digital platform supporting companies from outside the EU in entering European markets across pharmaceuticals, medical devices, food supplements, and cosmetics sectors.

Product overview

ENTERALIA BIOSCIENCE S.R.L. is a healthcare company operating in the European market. As a founding member of the European Healthcare Alliance (EHA), the company focuses on supporting innovative healthcare products from outside the EU in entering European markets, covering sectors including pharmaceuticals, medical devices, food supplements, and cosmetics. EHA provides a members-only digital platform for licensing opportunities and partner identification.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutic and Nutritional Solutions for Gastrointestinal, Iron Deficiency, and Gynecological Disorders Therapeutic and nutritional product line developed by ENTERALIA BIOSCIENCE S.R.L. addressing gastrointestinal disorders, iron deficiency, and gynecological disorders. Targeted at healthcare professionals and B2B distribution channels.
• European Healthcare Alliance (EHA) Market Access Services — Co-founded Platform Members-only digital platform supporting innovative healthcare products from outside the EU in entering European markets, covering pharmaceuticals, medical devices, food supplements, and cosmetics sectors. Provides asset licensing, partner identification, and access to qualified European consultants.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• NEMYSIS Ltd.coreStrategic or Co-development Partner · 1 January 2026NEMYSIS Ltd. is a co-founding partner of the European Healthcare Alliance (EHA), alongside ENTERALIA BIOSCIENCE S.r.l. and RICERCHIMA S.r.l. EHA was founded in 2026 as a digital platform to connect companies and consultants across the European healthcare sector.
• RICERCHIMA S.r.l.coreStrategic or Co-development Partner · 1 January 2026RICERCHIMA S.r.l. is a co-founding partner of the European Healthcare Alliance (EHA), alongside ENTERALIA BIOSCIENCE S.r.l. and NEMYSIS Ltd. EHA was founded in 2026 as a digital platform to connect companies and consultants across the European healthcare sector.
• European Healthcare Alliance (EHA)coreStrategic or Co-development Partner · 1 January 2026ENTERALIA BIOSCIENCE S.r.l. is a co-founder of the European Healthcare Alliance (EHA), a digital platform launched in 2026. EHA focuses on supporting innovative healthcare products from outside the EU in entering European markets, covering pharmaceuticals, medical devices, food supplements, and cosmetics sectors.

Recent moves2 records

Expansion highlights4 records

Broad incumbents

• Bureau Veritas: Global testing, inspection, and certification company serving healthcare, food, and cosmetics clients with regulatory compliance and market-access support. Comparable as a large diversified incumbent that overlaps with ENTERALIA's multi-vertical regulatory offering.
• SGS: World-leading testing, inspection, and certification company with a healthcare and life sciences practice covering pharmaceuticals, medical devices, food, and cosmetics. Comparable as a large diversified incumbent in the same regulatory/market-access services space.
• Intertek: Global assurance, testing, inspection, and certification provider with healthcare and consumer-products service lines relevant to pharma, devices, supplements, and cosmetics. Comparable as a broad incumbent operating in overlapping verticals.
• NSF International: Global testing, inspection, and certification organization with deep healthcare, dietary supplement, and cosmetics service lines, including EU regulatory support. Comparable as a broad incumbent in healthcare and consumer-product regulatory consulting adjacent to ENTERALIA's verticals.
• Eurofins Scientific: International group providing testing and laboratory services across food, pharmaceutical, cosmetics, and clinical sectors, with significant EU footprint. Comparable as a large incumbent whose testing and compliance services overlap with ENTERALIA's verticals.
• TÜV SÜD: International testing, certification, and auditing organization with active medical device, pharmaceutical, and cosmetics regulatory services in the EU. Comparable as a broad incumbent providing healthcare compliance and market-access services to non-EU entrants.

Direct peers

• Voisin Consulting Life Sciences: European regulatory and clinical strategy consultancy serving pharma, biotech, and medical device companies seeking EU market entry. Highly comparable to ENTERALIA in terms of customer profile, service focus, and EU-centric regulatory expertise.
• PharmaLex (Cencora PharmaLex): Specialized regulatory affairs, quality, and pharmacovigilance consulting for pharma and biotech across Europe and globally. Highly comparable as a regulatory and market-access services provider targeting healthcare companies navigating complex jurisdictions.

Emerging players

• ChemLinked (REACH24H): Regulatory intelligence and compliance platform focused on chemicals, food, cosmetics, and pharma entering regulated markets including the EU. Comparable as a content-plus-services platform assisting non-EU companies with EU regulatory entry.

Others

• Medidata Solutions (Dassault Systèmes): Digital platform supporting clinical trial execution and regulatory-grade data management for life sciences companies. Comparable as an enabling digital platform in the healthcare regulatory and trial-access ecosystem rather than a direct competitor.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/enteralia-bioscience-italia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENTERALIA BIOSCIENCE S.R.L.